Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...

Newly created role of Chief Patient Officer reinforces Compass’ vision of working to achieve broad and equitable access to COMP360, if approved “Steve has spent the past four years working to deeply ...

LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

U.S FDA has accepted IND application for COMP360 in PTSD, enabling the initiation of a Phase 2b/3 (COMP202) clinical trial in patients living with PTSD.